JP7818502B2 - 胃腸間質腫瘍を治療するためのリプレチニブ - Google Patents

胃腸間質腫瘍を治療するためのリプレチニブ

Info

Publication number
JP7818502B2
JP7818502B2 JP2022508506A JP2022508506A JP7818502B2 JP 7818502 B2 JP7818502 B2 JP 7818502B2 JP 2022508506 A JP2022508506 A JP 2022508506A JP 2022508506 A JP2022508506 A JP 2022508506A JP 7818502 B2 JP7818502 B2 JP 7818502B2
Authority
JP
Japan
Prior art keywords
patient
ripretinib
daily
administration
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022508506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544234A5 (cg-RX-API-DMAC10.html
JP2022544234A (ja
Inventor
ソト，ロドリゴ・ルイス
ローゼン，オリバー
ピットマン，ジャマ
Original Assignee
デシフェラ・ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デシフェラ・ファーマシューティカルズ，エルエルシー filed Critical デシフェラ・ファーマシューティカルズ，エルエルシー
Priority claimed from PCT/US2020/045876 external-priority patent/WO2021030405A1/en
Publication of JP2022544234A publication Critical patent/JP2022544234A/ja
Publication of JP2022544234A5 publication Critical patent/JP2022544234A5/ja
Priority to JP2025144362A priority Critical patent/JP2025176093A/ja
Application granted granted Critical
Publication of JP7818502B2 publication Critical patent/JP7818502B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022508506A 2019-08-12 2020-08-12 胃腸間質腫瘍を治療するためのリプレチニブ Active JP7818502B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025144362A JP2025176093A (ja) 2019-08-12 2025-09-01 胃腸間質腫瘍を治療するためのリプレチニブ

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962885797P 2019-08-12 2019-08-12
US62/885,797 2019-08-12
US201962904198P 2019-09-23 2019-09-23
US62/904,198 2019-09-23
US201962926281P 2019-10-25 2019-10-25
US62/926,281 2019-10-25
US201962936018P 2019-11-15 2019-11-15
US62/936,018 2019-11-15
US202062968927P 2020-01-31 2020-01-31
US202062968945P 2020-01-31 2020-01-31
US62/968,927 2020-01-31
US62/968,945 2020-01-31
US202063023921P 2020-05-13 2020-05-13
US202063023936P 2020-05-13 2020-05-13
US63/023,921 2020-05-13
US63/023,936 2020-05-13
PCT/US2020/045876 WO2021030405A1 (en) 2019-08-12 2020-08-12 Ripretinib for treating gastrointestinal stromal tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025144362A Division JP2025176093A (ja) 2019-08-12 2025-09-01 胃腸間質腫瘍を治療するためのリプレチニブ

Publications (3)

Publication Number Publication Date
JP2022544234A JP2022544234A (ja) 2022-10-17
JP2022544234A5 JP2022544234A5 (cg-RX-API-DMAC10.html) 2023-08-31
JP7818502B2 true JP7818502B2 (ja) 2026-02-20

Family

ID=74566909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022508506A Active JP7818502B2 (ja) 2019-08-12 2020-08-12 胃腸間質腫瘍を治療するためのリプレチニブ

Country Status (2)

Country Link
JP (1) JP7818502B2 (cg-RX-API-DMAC10.html)
IL (1) IL326329A (cg-RX-API-DMAC10.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222173A1 (en) 2017-05-30 2018-12-06 Deciphera Pharmaceuticals, Inc. Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222173A1 (en) 2017-05-30 2018-12-06 Deciphera Pharmaceuticals, Inc. Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Cell，2019年05月01日，Vol.35，No.535，p.738-751
INITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFRINHIBITOR, IN PATIENTS (PTS) WITH GASTROINTESTINAL STROMAL TUMOR (GIST) BY NUMBER OF PRIOR REGIMENS，[online]，2018年10月19日，[2024年7月29日検索]，＜URL：https://investors.deciphera.com/news-releases/news-release-details/deciphera-pharmaceuticals-initiates-pivotal-phase-3-clinical＞
新しい GIST診療ガイドラインを読み解く～再発GISTの予後向上に向けて～，[online]，2014年07月11日，[2024年7月29日検索]，＜URL：https://medical-tribune.co.jp/mtpronews/dmi/dmi140711.pdf＞

Also Published As

Publication number Publication date
JP2022544234A (ja) 2022-10-17
IL326329A (en) 2026-04-01

Similar Documents

Publication Publication Date Title
US12023327B2 (en) Methods of treating gastrointestinal stromal tumors
JP2022544234A (ja) 胃腸間質腫瘍を治療するためのリプレチニブ
EA049612B1 (ru) Рипретиниб для лечения желудочно-кишечных стромальных опухолей
HK40074594B (en) Ripretinib for treating gastrointestinal stromal tumors
HK40074594A (en) Ripretinib for treating gastrointestinal stromal tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260209

R150 Certificate of patent or registration of utility model

Ref document number: 7818502

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150